Compounds > dabi

Page last updated: 2024-12-06

dabi

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DABI: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	67954
CHEMBL ID	1713837
MeSH ID	M0042700

Synonyms (18)

Synonym
NCIMECH_000523
NCI60_041763
dabi
mls002694383 ,
OPREA1_497142
NCIOPEN2_004216
smr001560312
4-(inden-1-ylidenemethyl)-n,n-dimethylaniline
HMS3091A08
CHEMBL1713837
cid_67954
bdbm83708
4-(1-indenylidenemethyl)-n,n-dimethylaniline
[4-(inden-1-ylidenemethyl)phenyl]-dimethyl-amine
4-(inden-1-ylidenemethyl)-n,n-dimethyl-aniline
AKOS030229104
(e)-4-((1h-inden-1-ylidene)methyl)-n,n-dimethylaniline
PD028189

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	14.1254	0.6310	35.7641	100.0000	AID504339
BRCA1	Homo sapiens (human)	Potency	1.5849	0.8913	7.7225	25.1189	AID624202
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	3.1623	0.7079	12.1943	39.8107	AID720542
PINK1	Homo sapiens (human)	Potency	12.5893	2.8184	18.8959	44.6684	AID624263
Parkin	Homo sapiens (human)	Potency	12.5893	0.8199	14.8306	44.6684	AID624263
chromobox protein homolog 1	Homo sapiens (human)	Potency	50.1187	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	1.6360	0.0041	9.9848	25.9290	AID504444
eyes absent homolog 2 isoform a	Homo sapiens (human)	Potency	3.7939	1.1998	14.6419	50.1187	AID720540
DNA dC->dU-editing enzyme APOBEC-3F isoform a	Homo sapiens (human)	Potency	35.4813	0.0259	11.2398	31.6228	AID602313
C-terminal-binding protein 1	Homo sapiens (human)	Potency	7.5699	0.3014	9.3210	19.0148	AID720541
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
endoribonuclease toxin MazF	Escherichia coli str. K-12 substr. MG1655	EC50 (µMol)	59.8500	3.9600	9.5157	17.4000	AID588481; AID588502
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	C-terminal-binding protein 1	Homo sapiens (human)
protein phosphorylation	C-terminal-binding protein 1	Homo sapiens (human)
negative regulation of cell population proliferation	C-terminal-binding protein 1	Homo sapiens (human)
viral genome replication	C-terminal-binding protein 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	C-terminal-binding protein 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	C-terminal-binding protein 1	Homo sapiens (human)
synaptic vesicle endocytosis	C-terminal-binding protein 1	Homo sapiens (human)
white fat cell differentiation	C-terminal-binding protein 1	Homo sapiens (human)
regulation of cell cycle	C-terminal-binding protein 1	Homo sapiens (human)
synaptic vesicle clustering	C-terminal-binding protein 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	C-terminal-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Process	via Protein(s)	Taxonomy
transcription corepressor binding	C-terminal-binding protein 1	Homo sapiens (human)
chromatin binding	C-terminal-binding protein 1	Homo sapiens (human)
transcription corepressor activity	C-terminal-binding protein 1	Homo sapiens (human)
protein binding	C-terminal-binding protein 1	Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	C-terminal-binding protein 1	Homo sapiens (human)
protein domain specific binding	C-terminal-binding protein 1	Homo sapiens (human)
identical protein binding	C-terminal-binding protein 1	Homo sapiens (human)
NAD binding	C-terminal-binding protein 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	C-terminal-binding protein 1	Homo sapiens (human)
DNA-binding transcription factor binding	C-terminal-binding protein 1	Homo sapiens (human)
transcription coactivator activity	C-terminal-binding protein 1	Homo sapiens (human)
transcription coregulator binding	C-terminal-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Process	via Protein(s)	Taxonomy
nucleus	C-terminal-binding protein 1	Homo sapiens (human)
nucleoplasm	C-terminal-binding protein 1	Homo sapiens (human)
presynaptic active zone cytoplasmic component	C-terminal-binding protein 1	Homo sapiens (human)
glutamatergic synapse	C-terminal-binding protein 1	Homo sapiens (human)
GABA-ergic synapse	C-terminal-binding protein 1	Homo sapiens (human)
transcription repressor complex	C-terminal-binding protein 1	Homo sapiens (human)
nucleus	C-terminal-binding protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 112.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	112.07 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	201.65 (26.88)
Search Engine Supply Index	2.03 (0.95)

This Compound (112.07)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0
Hepatocellular Carcinoma [description not available]	0	1.94	1	0
Cancer of Liver [description not available]	0	1.94	1	0
Experimental Neoplasms [description not available]	0	1.94	1	0
Cancer of Ovary [description not available]	0	1.94	1	0
Sarcoma, Epithelioid [description not available]	0	1.94	1	0
Cancer of Skin [description not available]	0	1.94	1	0
Experimental Mammary Neoplasms [description not available]	0	1.94	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	1.94	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	1.94	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	1.94	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	1.94	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	1.94	1	0